AccessibilityHelpAbout Us
Eagle Pharmaceuticals logo

Eagle Pharmaceuticals(OTC) EGRX

Market Cap$2.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-99%
5 Year-100%
1 Year-95%
1 Month-73%
$0.16
-78.64%
-0.59Today
Eagle Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.162026-09-11
Eagle Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-78.49%USD 0.752026-09-03
1 month-72.89%USD 0.602026-08-12
3 month-73.12%USD 0.602026-06-12
Year to date-76.96%USD 0.702025-12-31
1 year-94.96%USD 3.202025-09-11
3 year-99.01%USD 16.292023-09-12
5 year-99.69%USD 51.702021-09-10
Since inception-98.74%USD 12.832014-02-12

Eagle Pharmaceuticals Financials at a Glance

Market Cap

$2.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$257.55M

Net Income (TTM)

$15.57M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-20.27 (Low)

Price

$0.16

Volume

1,076

Open

$0.65

Previous Close

$0.16

Daily Range

$0.16 - $0.75

52-Week Range

$0.00 - $3.73

Estimated Earnings Date

Mar 9, 2026

EGRX News

Pills From a Pill Bottle

3 Stocks the Smartest Investors Are Buying Right Now

Travis HoiumJul 20, 2017
drugs and money images

3 Top Biotech Stocks to Buy in 2017

Brian FeroldiMar 26, 2017
dividends getty people catching money

Why Eagle Pharmaceuticals, Inc. Is Soaring 21.6% Today

Todd CampbellNov 2, 2016
man money in air

Why Eagle Pharmaceuticals Inc. Flew 38.5% Higher in August

Brian FeroldiSep 9, 2016
rocket flickr Steve Jurvetson

Why Eagle Pharmaceuticals, Inc. Skyrocketed 27.8% Today

Todd CampbellJun 10, 2016
Longview3

Here's Why Eagle Pharmaceuticals' Stock Cratered Today

George Budwell, PhDMar 18, 2016
NASDAQ_studio

The Best Biotech Stocks in 2015

Keith SpeightsDec 28, 2015
pills and dollars flickr user chris potter

3 Moneymaking Biotech Stocks to Consider Buying

Todd CampbellJul 5, 2015
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing innovative product candidates for critical care, oncology, and central nervous system diseases. The company is headquartered in Woodcliff Lake, New Jersey, and has a diverse portfolio of products aimed at addressing significant medical needs.

Products and Services
  • RYANODEX for malignant hyperthermia
  • BELRAPZO and BENDEKA for chronic lymphocytic leukemia
  • PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection
Growth Outlook
  • Recent quarterly revenue reached $64.6 million, showcasing strong market demand
  • Gross profit margin improved to 73.9% in Q2 2023, indicating operational efficiency
  • Strategic collaborations with Tyme Technologies and Combioxin enhance product pipeline
Financial Highlights
  • Net income of $5.16 million reported for Q2 2023, reflecting profitability
  • Operating income margin of 15.9% in Q2 2023 demonstrates effective cost management
  • Current ratio of 1.70 indicates strong liquidity position
Eagle Pharmaceuticals, Inc. has established itself as a key player in the specialty and generic drug manufacturing industry. The company's focus on innovative therapies positions it well for future growth, particularly in oncology and critical care markets. Recent financial performance highlights a solid revenue stream and profitability, which may attract potential investors looking for opportunities in the healthcare sector. The strategic partnerships and collaborations further enhance the company's growth potential, making it a noteworthy consideration for those interested in the pharmaceutical industry.
AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

135

CEO

Scott L. Tarriff, MBA

Website

www.eagleus.com

Headquarters

Woodcliff Lake, NJ 07677, US

EGRX Financials

Key Financial Metrics (TTM)

Gross Margin

70.01%

Operating Margin

25.57%

Net Income Margin

11.26%

Return on Equity

17.39%

Return on Capital

26.87%

Return on Assets

8.78%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

13.02M

Volume

1.08K

Avg. Volume

6.23K

Financials (TTM)

Gross Profit

$179.88M

Operating Income

$23.65M

EBITDA

$56.98M

Operating Cash Flow

-$9.32M

Capital Expenditure

-$74.00K

Free Cash Flow

-$9.39M

Cash & ST Invst.

$15.35M

Total Debt

$71.62M

Eagle Pharmaceuticals Performance Analysis

Eagle Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 171,546,000N/A
20222022-12-31USD 316,610,00084.6%
Eagle Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30-11.1%
Q42022-12-31-7.9%
Q12023-03-319.2%
Q22023-06-30-2.5%
Eagle Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.66N/A
20222022-12-31USD 2.73N/A
Eagle Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-3063.5%
Q42022-12-31329.6%
Q12023-03-31-29.0%
Q22023-06-30-11.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$64.65M

-12.8%

Gross Profit

$47.79M

-5.3%

Gross Margin

73.92%

N/A

Market Cap

$2.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$15.56K

N/A

Employees

135

N/A

Net Income

$5.16M

+154.6%

EBITDA

$16.33M

+641.1%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$15.35M

-58.0%

Total Debt

$71.62M

+33.6%

Accounts Receivable

$116.28M

+33.0%

Inventory

$42.48M

-26.4%

Long Term Debt

$62.74M

+107.2%

Short Term Debt

$9.72M

-58.3%

Return on Assets

8.78%

N/A

Return on Invested Capital

27.44%

N/A

Free Cash Flow

-$132.00K

-100.3%

Operating Cash Flow

-$126.00K

-100.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BLMHBlum Holdings, Inc.
$0.22+7.21%
ECGSEco-Growth Strategies Inc.
$0.05+0.00%
CNFHFCanaFarma Hemp Products Corp.
$0.00+0.00%
VPHIFValeo Pharma Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
KHCKraft Heinz
$24.60+0.01%
ACVAACV Auctions
$10.41+0.44%
TNONTenon Medical
$5.93+0.12%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.16+0.03%

Questions About EGRX

What is the current price of Eagle Pharmaceuticals?

Eagle Pharmaceuticals is trading at $0.16 per share.

What is the 52-week range for Eagle Pharmaceuticals?

Over the past 52 weeks, Eagle Pharmaceuticals has traded between $0.00 and $3.73.

How much debt does Eagle Pharmaceuticals have?

As of the most recent reporting period, Eagle Pharmaceuticals reported total debt of $65.51M.

How much cash does Eagle Pharmaceuticals have on hand?

Eagle Pharmaceuticals reported $55.32M in cash and cash equivalents in its most recent financial results.

What is Eagle Pharmaceuticals’s dividend yield?

Eagle Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services